Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2011 | Original Article

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma

Authors: Henriette Ingrid Melzer, Eva Coppenrath, Irene Schmid, Michael H. Albert, Dietrich von Schweinitz, Coral Tudball, Peter Bartenstein, Thomas Pfluger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2011

Abstract

Purpose

To analyse different uptake patterns in ¹²³I-MIBG scintigraphy/SPECT imaging and ¹⁸F-FDG PET in paediatric neuroblastoma patients.

Methods

We compared 23 ¹²³I-MIBG scintigraphy scans and 23 ¹⁸F-FDG PET scans (mean interval 10 days) in 19 patients with a suspected neuroblastic tumour (16 neuroblastoma, 1 ganglioneuroblastoma, 1 ganglioneuroma and 1 opsomyoclonus syndrome). SPECT images of the abdomen or other tumour-affected regions were available in all patients. Indications for ¹⁸F-FDG PET were a ¹²³I-MIBG-negative tumour, a discrepancy in ¹²³I-MIBG uptake compared to the morphological imaging or imaging results inconsistent with clinical findings. A lesion was found by ¹²³I-MIBG scintigraphy and/or ¹⁸F-FDG PET and/or morphological imaging.

Results

A total of 58 suspicious lesions (mean lesion diameter 3.8 cm) were evaluated and 18 were confirmed by histology and 40 by clinical follow-up. The sensitivities of ¹²³I-MIBG scintigraphy and ¹⁸F-FDG PET were 50% and 78% and the specificities were 75% and 92%, respectively. False-positive results (three ¹²³I-MIBG scintigraphy, one ¹⁸F-FDG PET) were due to physiological uptake or posttherapy changes. False-negative results (23 ¹²³I-MIBG scintigraphy, 10 ¹⁸F-FDG PET) were due to low uptake and small lesion size. Combined ¹²³I-MIBG scintigraphy/¹⁸F-FDG PET imaging showed the highest sensitivity of 85%. In 34 lesions the ¹²³I-MIBG scintigraphy and morphological imaging findings were discrepant. ¹⁸F-FDG PET correctly identified 32 of the discrepant findings. Two bone/bone marrow metastases were missed by ¹⁸F-FDG PET.

Conclusion

¹²³I-MIBG scintigraphy and ¹⁸F-FDG PET showed noticeable differences in their uptake patterns. ¹⁸F-FDG PET was more sensitive and specific for the detection of neuroblastoma lesions. Our findings suggest that a ¹⁸F-FDG PET scan may be useful in the event of discrepant or inconclusive findings on ¹²³I-MIBG scintigraphy/SPECT and morphological imaging.

Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma. time trends and regional differences in Europe, 1978–1992. Eur J Cancer. 2001;37:722–9.PubMedCrossRef

Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403–18.PubMed

DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181–9.PubMedCrossRef

Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34.PubMedCrossRef

Balwierz W, Wieczorek A, Klekawka T, Garus K, Bolek-Marzec K, Perek D, et al. Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group. Przegl Lek. 2010;67:387–92.PubMed

Perwein T, Lackner H, Sovinz P, Benesch M, Schmidt S, Schwinger W, et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr Blood Cancer. 2011; doi:10.1002/pbc.23036.

Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med. 2003;47:31–40.PubMed

Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552–8.PubMedCrossRef

Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:388–402.PubMed

10.

Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma – the pitfalls of iodine-123-MIBG scans. J Nucl Med. 1990;31:129–34.PubMed

11.

Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000;35:153–5.PubMedCrossRef

12.

Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003;21:1082–6.PubMedCrossRef

13.

Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743–50.PubMed

14.

Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172–88.PubMed

15.

Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237–43.PubMedCrossRef

16.

Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.PubMed

17.

Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26.PubMedCrossRef

18.

Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003;30:B45–50.PubMedCrossRef

19.

Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35:1581–8.PubMedCrossRef

20.

Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.PubMedCrossRef

21.

Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010;95:2596–606.PubMedCrossRef

22.

Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol. 2003;181:1115–24.PubMed

23.

Connolly LP, Drubach LA, Ted Treves S. Applications of nuclear medicine in pediatric oncology. Clin Nucl Med. 2002;27:117–25.PubMedCrossRef

24.

Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397–405.PubMed

25.

Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679–88.PubMed

26.

Pfluger T, Schmid I, Coppenrath E, Weiss M. Modern nuclear medicine evaluation of neuroblastoma. Q J Nucl Med Mol Imaging. 2010;54:389–400.PubMed

27.

McDowell H, Losty P, Barnes N, Kokai G. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2009;52:552.CrossRef

28.

Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27:1041–6.PubMedCrossRef

29.

Colavolpe C, Guedj E, Cammilleri S, Taieb D, Mundler O, Coze C. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51:828–31.PubMedCrossRef

30.

Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol. 2000;34:237–41.PubMedCrossRef

31.

Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343–9.PubMedCrossRef

32.

Goo HW. Whole-body MRI of neuroblastoma. Eur J Radiol. 2010;75:306–14.PubMedCrossRef

Title: 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma
Authors: Henriette Ingrid Melzer
Eva Coppenrath
Irene Schmid
Michael H. Albert
Dietrich von Schweinitz
Coral Tudball
Peter Bartenstein
Thomas Pfluger
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1843-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2011

90Y Time-of-flight PET/MR on a hybrid scanner following liver radioembolisation (SIRT)

Lymphoscintigraphy and SPECT/CT using 99mTc filtered sulphur colloid in chylothorax

Predictive value of brain perfusion SPECT for rTMS response in pharmacoresistant depression

Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis

What we have learned from Fukushima

Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin’s disease